Latest Neurizon Therapeutics News & Updates

See the latest news and media coverage for Neurizon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Neurizon Therapeutics (Neurizon)

Biotechnology company developing treatments for neurodegenerative diseases

neurizon.com
Headquarters
Melbourne, Australia
Company type
Public company
Number of employees
2–15
Industry
Pharmaceuticals

Last updated

Latest news about Neurizon Therapeutics (Neurizon)

In short: Neurizon accelerated its ALS clinical trial timelines, secured over $44 million in funding, and appointed Dr. Chris Bremer as the new CEO.

Company announcements

Neurizon

Neurizon completes HEALEY ALS trial enrolment early

Topline results for NUZ-001 accelerated to Q2 2027, with 250 participants enrolled in under five months.

Unlock all announcements with a

Media coverage

NeurologyLive

HEALEY-ALS Platform Trial Undergoes Amendments for ALS Therapy NUZ-001 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Neurizon Therapeutics announced updates to the HEALEY-ALS trial and promising NUZ-001 results, signaling a major step forward in ALS treatment research.

Unlock all articles with a

Never miss news about Neurizon

Track Neurizon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurizon competitors & trending companies

Browse news for competitors to Neurizon and other trending companies.